Friday, July 20, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan

(July 11, 2018)

TOKYO, Jul 11, 2018 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. will launch the oral antifungal agent NAILIN Capsules 100mg in Japan on July 27, 2018.

Sato Pharmaceutical obtained marketing and manufacturing approval for NAILIN Capsules 100mg as an oral treatment for onychomycosis. This product is the first new treatment for the disease in approximately 20 years. NAILIN Capsules 100mg contains the active ingredient fosravuconazole L-lysine ethanolate which was discovered by Eisai and has improved bioavailability compared to ravuconazole.

Caused by the invasion of the nails by the Trichophyton fungus via the skin of the hands and feet, onychomycosis is a fungal infection that induces symptoms such as the clouding and thickening of nails as well as hyperkeratosis in the area surrounding the nail. Onychomycosis affects 1 in every 10 Japanese people with an estimated approximately 11 million sufferers in Japan, and incidence rises with age. Although it is an easy disease to leave untreated as it is not associated with pain or itchiness, if the disease progresses, various symptoms may occur such as pain from misshapen nails, difficulty in putting on shoes and pain upon walking, and many patients are concerned about reduction in QOL (quality of life). Furthermore, it is possible for Trichophyton to infect other people by sharing slippers, bathmats and other mediums.

In a Phase III clinical study conducted by Sato Pharmaceutical of NAILIN Capsules 100mg administered orally once daily for 12 weeks in patients with onychomycosis conducted in Japan, superior efficacy was confirmed for NAILIN Capsules 100mg compared to placebo.

Going forward, Sato Pharmaceutical will conduct marketing of NAILIN Capsules 100mg, while Sato Pharmaceutical and Eisai are jointly providing information on its proper use. By expanding the options for treating onychomycosis through NAILIN Capsules 100mg, the two companies are striving to further contribute to the treatment of onychomycosis patients.

About Sato Pharmaceutical Co., Ltd.

Sato Pharmaceutical Co., Ltd., operating under its corporate philosophy of 'Healthcare Innovation', is a pharmaceutical company that provides effective, safe, and highquality products for practicing selfcare, while always keeping the health of its customers in mind. In addition to its main consumer healthcare business, Sato Pharmaceutical also develops and provides highly original products primarily in the field of dermatology.

Regarding ethical pharmaceuticals, through the marketing of NAILIN Capsules 100 mg in addition to the onychomycosis treatment LUCONAC Solution 5% launched on April 25, 2016, Sato Pharmaceutical is able to provide both externally and internally administered medicines as options for the treatment of onychomycosis. Going forward, Sato Pharmaceutical is expanding promotion aimed at establishing a brand with these products as two pillars of onychomycosis treatment, and is striving to continue growing as a leading company in the treatment of onychomycosis that is trusted by healthcare professionals.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Sato Pharmaceutical Co., Ltd.Public Relations Department +81-(0)3-5412-7354Eisai Co., Ltd.Public Relations Department +81-(0)3-3817-5120
Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

Page: 1


Related Keywords:TYO:4523, OTCMKTS:ESALF, PK:ESALY
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

    Cancer
  • Mesothelioma is a Deadly Cancer and itís Completely Preventable
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines